About
Therapies targeting master regulators in cancer
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
2
As Collaborator
1
Total Enrollment
216
By Phase
PHASE1: 3
By Status
RECRUITING: 3
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06414434Collaborator
BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma
PHASE1Recruiting
24 participants
Started: Sep 30, 2024 · Completed: Jun 1, 2027
NCT04872166Lead Sponsor
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
PHASE1Recruiting
112 participants
Started: Jun 7, 2021 · Completed: May 31, 2027
NCT04243785Lead Sponsor
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
PHASE1Recruiting
80 participants
Started: Jan 6, 2020 · Completed: Mar 31, 2027
Locations (1)
Headquarters
Brookline, MA, United States
Map
Loading map...